Clinical trial · Observational
Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada
Patients With Upper Gastrointestinal Cancer Enrolled in a Patient Support Program to Receive Nivolumab in the Adjuvant Setting: Real World Data From Canada
NCT06361563CI-TRIAL-00076006completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Upper Gastrointestinal Cancer | Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nivolumab | Drug | Nivolumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Participants treated with adjuvant nivolumab
- interventionNames
- Drug: Nivolumab
Primary outcomes (7)
- measure
- Participant sociodemographics
- timeFrame
- Baseline
- measure
- Participant Eastern Cooperative Oncology Group (ECOG) score
- timeFrame
- Baseline
- measure
- Participant histology results
- timeFrame
- Baseline
- measure
- Participant comorbidities
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Enrolled in Bristol-Myers Squibb GastroEsophageal Opdivo in Resected Patients with Residual Pathological Disease Patient Support Program (GEORge PSP) in Canada * Patients who have consented to the use of their de-identified data generated from information collected in the course of the GEORge PSP Exclusion Criteria: * Aged \<18 years * Did not receive concurrent chemoradiotherapy prior to surgery * Positive margins following resection * No residual disease following complete resection
References
Publications (0)
Data not yet available
No reference posted for this study.